| Id: | acc0543 |
| Group: | 1sens |
| Protein: | HK-2 |
| Gene Symbol: | HK2 |
| Protein Id: | P52789 |
| Protein Name: | HXK2_HUMAN |
| PTM: | phosphorylation |
| Site: | Ser473 |
| Site Sequence: | ADQHRARQKTLEHLQLSHDQL |
| Disease Category: | Cancer |
| Disease: | Hepatocellular Carcinoma |
| Disease Subtype: | |
| Disease Cellline: | HepG2 |
| Disease Info: | |
| Drug: | limonin |
| Drug Info: | - |
| Effect: | modulate |
| Effect Info: | "By blocking the phosphorylation of hexokinase-2, limonin can inhibit tumor glycolysis and induce apoptosis of hepatocellular carcinoma cells." |
| Note: | |
| Score: | 4.0 |
| Pubmed(PMID): | 30013360 |
| Sentence Index: | 30013360_0 |
| Sentence: | "By blocking hexokinase-2 phosphorylation, limonin suppresses tumor glycolysis and induces cell apoptosis in hepatocellular carcinoma." |
Sequence & Structure:
MIASHLLAYFFTELNHDQVQKVDQYLYHMRLSDETLLEISKRFRKEMEKGLGATTHPTAAVKMLPTFVRSTPDGTEHGEFLALDLGGTNFRVLWVKVTDNGLQKVEMENQIYAIPEDIMRGSGTQLFDHIAECLANFMDKLQIKDKKLPLGFTFSFPCHQTKLDESFLVSWTKGFKSSGVEGRDVVALIRKAIQRRGDFDIDIVAVVNDTVGTMMTCGYDDHNCEIGLIVGTGSNACYMEEMRHIDMVEGDEGRMCINMEWGAFGDDGSLNDIRTEFDQEIDMGSLNPGKQLFEKMISGMYMGELVRLILVKMAKEELLFGGKLSPELLNTGRFETKDISDIEGEKDGIRKAREVLMRLGLDPTQEDCVATHRICQIVSTRSASLCAATLAAVLQRIKENKGEERLRSTIGVDGSVYKKHPHFAKRLHKTVRRLVPGCDVRFLRSEDGSGKGAAMVTAVAYRLADQHRARQKTLEHLQLSHDQLLEVKRRMKVEMERGLSKETHASAPVKMLPTYVCATPDGTEKGDFLALDLGGTNFRVLLVRVRNGKWGGVEMHNKIYAIPQEVMHGTGDELFDHIVQCIADFLEYMGMKGVSLPLGFTFSFPCQQNSLDESILLKWTKGFKASGCEGEDVVTLLKEAIHRREEFDLDVVAVVNDTVGTMMTCGFEDPHCEVGLIVGTGSNACYMEEMRNVELVEGEEGRMCVNMEWGAFGDNGCLDDFRTEFDVAVDELSLNPGKQRFEKMISGMYLGEIVRNILIDFTKRGLLFRGRISERLKTRGIFETKFLSQIESDCLALLQVRAILQHLGLESTCDDSIIVKEVCTVVARRAAQLCGAGMAAVVDRIRENRGLDALKVTVGVDGTLYKLHPHFAKVMHETVKDLAPKCDVSFLQSEDGSGKGAALITAVACRIREAGQR
Select PDB:
No data.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACNo intensity data of this site,
show all other sites!
| HK2-Ser122 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.707 | ||||
| HGSC | |||||
| ccRCC | |||||
| GBM | 0.707 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| HK2-Thr519 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | 1.064 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | -0.144 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | -0.92 | ||||
| SPHK2-Ser328 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -0.057 | ||||
| COAD | -0.098 | ||||
| HGSC | 0.298 | ||||
| ccRCC | -1.572 | ||||
| GBM | -1.159 | ||||
| HNSC | 0.613 | ||||
| LUAD | 0.371 | ||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | 1.603 | ||||
| SPHK2-Ser334 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | -0.707 | ||||
| ccRCC | |||||
| GBM | 0.707 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| SPHK2-Ser340 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 0.707 | ||||
| HGSC | |||||
| ccRCC | |||||
| GBM | -0.707 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| SPHK2-Ser355 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 1.488 | ||||
| COAD | -0.534 | ||||
| HGSC | -0.724 | ||||
| ccRCC | -0.575 | ||||
| GBM | -0.116 | ||||
| HNSC | 0.695 | ||||
| LUAD | 0.21 | ||||
| LUSC | -1.934 | ||||
| non_ccRCC | 1.102 | ||||
| PDAC | |||||
| UCEC | 0.387 | ||||
| SPHK2-Ser425 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 0.365 | ||||
| HGSC | 0.236 | ||||
| ccRCC | |||||
| GBM | -1.626 | ||||
| HNSC | -0.055 | ||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | 1.08 | ||||
| UCEC | |||||
| SPHK2-Ser428 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 0.707 | ||||
| HGSC | -0.707 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| SPHK2-Ser48 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | 0.707 | ||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | -0.707 | ||||
| PDAC | |||||
| UCEC | |||||
| SPHK2-Thr330 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 0.707 | ||||
| HGSC | -0.707 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| SPHK2-Thr343 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 0.707 | ||||
| HGSC | |||||
| ccRCC | |||||
| GBM | -0.707 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| SPHK2-Thr345 | |
|---|---|
| Cancer | Intensity |
| BRCA | |
| COAD | |
| HGSC | |
| ccRCC | -0.707 |
| GBM | |
| HNSC | |
| LUAD | 0.707 |
| LUSC | |
| non_ccRCC | |
| PDAC | |
| UCEC | |
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| T | 473 | U | Breast cancer | Phosphorylation | 29985480 |
| T | 473 | U | Colon cancer | Phosphorylation | 30877036 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
